Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study
Sangro, B, Yau, T, Hsu, C, Kudo, M, Crocenzi, T.S, Choo, S.-P, Meyer, T, Welling, T.H, Yeo, W, Chopra, A, Baakili, A, dela Cruz, C, Lang, L, Neely, J, Melero, I, El-Khoueiry, A.B, Trojan, J
Published in Journal of hepatology (2017)
Published in Journal of hepatology (2017)
Get full text
Journal Article
P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis
Sangro, B, El-Khoueiry, A.B, Crocenzi, T.S, Welling, T.H, Feely, W, Anderson, J.A, Cruz, C. dela, Melero, I
Published in Journal of hepatology (01.04.2015)
Published in Journal of hepatology (01.04.2015)
Get full text
Journal Article
746P Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model
Sebesta, C., Chung, V., El-Khoueiry, A.B., Tilley, J., Windsor, W., Stouch, T., Ellingboe, J., Zhang, C., Gaweco, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
749P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Meyer, T., Kelley, R.K., Mangeshkar, M., Cheng, A.-L., El-Khoueiry, A.B., Abou-Alfa, G.K.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Meyer, T., Kelley, R.K., Mangeshkar, M., Cheng, A.-L., El-Khoueiry, A.B., Abou-Alfa, G.K.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Alistar, A., Mahalingam, D., Barve, M., Borad, M., Babiker, H., Xie, H., Choi, B., Ahn, J., Choi, J., Ahn, K., Ryu, S., Kim, J., Yu, D., Lee, S-J., Jeon, B., Proniuk, S., Kim, J., Nam, K., El-Khoueiry, A.B.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma
Wilky, B., Trent, J.C., Gordon, M., El-Khoueiry, A.B., Bullock, A., Henick, B.S., Schwartz, G.K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O'Day, S.J., Tsimberidou, A.M.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors
Hanna, D., Cassier, P., Alistar, A., Sharma, S., Matrana, M., George, B., El-Khoueiry, A.B., Okano, F., Von Hoff, D.D., Blay, J.Y.
Published in European journal of cancer (1990) (01.10.2022)
Published in European journal of cancer (1990) (01.10.2022)
Get full text
Journal Article
754P A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I
El-Khoueiry, A.B., Lopez, J.S., Saavedra, O., Awad, M., Thomas, J., Tiu, C., Garralda, E., Rehbein, B., Hintzen, G., Pietzko, K., Raab, C., Rajkovic, E., Ravenstijn, P., Rivas, D., Emig, M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)
Spira, A., Mehra, R., Mantia, C., Babiker, H., Borad, M., Cervantes, A., Garralda, E., Mahipal, A., Paz-Ares, L., Hatzis, C., Liu, A., Raue, A., Gan, J., Adrian, F., Manenti, L., El-Khoueiry, A.B.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Yau, T., Meyer, T., Kelley, R.K., Mangeshkar, M., Cheng, A.-L., El-Khoueiry, A.B., Abou-Alfa, G.K.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Shapiro, G.I., Basu, B., El-Khoueiry, A.B., Postel-Vinay, S., Im, S-A., Rha, S.Y., Friedman, C.F., Italiano, A., Kim, Y.M., Lim, M-C., Roux, R., Liu, J.F., Brown, M., Webb, B.W., Lukashchuk, N., Dean, E.J., Nehra, J., Loembé, B., Krebs, M.G.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet, J.M., El-Khoueiry, A.B., Vogel, A., Madoff, D.C., Finn, R.S., Ogasawara, S., Ren, Z., Mody, K., Li, J. Jing, Siegel, A.B., Dubrovsky, L., Kudo, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
61P Gender and race/ethnicity differences in outcomes of biliary cancers (BC): A SEER database analysis
Lenz, H.J., Luo, C., Jayachandran, P., Arai, H., Wang, J., Kawanishi, N., Soni, S., El-Khoueiry, A.B., Zhang, W., Millstein, J., Battaglin, F.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
Galle, P.R., Kim, R.D., Sung, M.W., Harris, W.P., Waldschmidt, D., Cabrera, R., Mueller, U., Nakajima, K., Ishida, T., El-Khoueiry, A.B.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
El-Khoueiry, A.B., Trojan, J., Meyer, T., Yau, T., Melero, I., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Kang, Y.-K., Yeo, W., Chopra, A., Soleymani, S., Yao, J., Neely, J., Tschaika, M., Welling, T.H., Sangro, B.
Published in Annals of oncology (01.04.2024)
Published in Annals of oncology (01.04.2024)
Get full text
Journal Article
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., Knox, J., He, A.R., El-Rayes, B., Acosta-Rivera, M., Lim, H.Y., Soleymani, S., Yao, J., Neely, J., Tschaika, M., Hsu, C., El-Khoueiry, A.B.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article
525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Ku, G., Bendell, J.C., Tolcher, A.W., Hurvitz, S.A., Krishnamurthy, A., El-Khoueiry, A.B., Patnaik, A., Shroff, R.T., Noonan, A., Hahn, N.M., Matrana, M., Zettl, M., Aviano, K., Mar, L., Jolicoeur, P., Olwill, S., Bruns, I., Piha-Paul, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Chan, S.L., Miksad, R., Cicin, I., Chen, Y., Klumpen, H.J., Kim, S., Lin, Z.Z., Youkstetter, J., Sen, S., Cheng, A.-L., El-Khoueiry, A.B., Meyer, T., Kelley, R.K., Abou-Alfa, G.K.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article